Breaks Categories: News

ThursdayAug 14, 2025 10:48 am

NetworkNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) Q2 2025 Revenue Jumps 154% on Strong Demand for Motion and Fast Motion Shafts

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company delivering physics-based performance innovations, reported Q2 2025 revenue of $2.1 million, up 154% from $813,000 in the year-ago quarter, with gross margin improving to 67.6% from 60.1%. First-half 2025 revenue rose 182% to $3.3 million, while net loss narrowed to $2.1 million from $2.4 million. The company cited rapid adoption of its new Fast Motion shaft—launched April 29—which generated more than $696,000 in gross sales in its first two months and has already surpassed 2,200 units sold in Q3. Additional highlights included surpassing 50 professional users across major tours, expanding global…

Continue Reading

ThursdayAug 14, 2025 10:15 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN), a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and said it has sufficient cash runway into Q1 2026. The company plans to meet with the FDA this quarter to review survival data for lead candidate CNM-Au8 in amyotrophic lateral sclerosis (ALS) and is preparing analyses of NIH-sponsored Expanded Access Program neurofilament light biomarker data, expected in Q4. These steps are intended to support a potential New Drug Application submission under the FDA’s accelerated approval pathway for ALS by year-end 2025. Management said its focus remains on delivering an impactful therapy to the…

Continue Reading

ThursdayAug 14, 2025 10:10 am

NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 Phase 1a enrollment, positioning it for Phase 1b/2 studies in high-value indications. LP-184 has FDA Fast Track and multiple Rare Pediatric Disease designations and showed significant survival gains in ATRT models. Lantern strengthened its IP with a European patent allowance for LP-284 and publication of…

Continue Reading

ThursdayAug 14, 2025 9:25 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL is actively enrolling, with results anticipated in 2026. Soligenix also completed a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease, achieving its primary objective of demonstrating biological efficacy, and transferred manufacturing of synthetic hypericin to the U.S. under its Sterling…

Continue Reading

ThursdayAug 14, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic agreement with standard 12-lead ECGs. HeartBeam is executing commercial readiness plans, including establishing manufacturing, logistics, and cardiologist review services, with launch expected after clearance. Additional highlights include an accepted AI algorithm abstract for HRX Live 2025, issuance of a new international patent bringing the total…

Continue Reading

WednesdayAug 13, 2025 12:45 pm

NetworkNewsBreaks – D. Boral ARC Acquisition I Corp. (NASDAQ: BCARU) Closes $250 Million IPO

D. Boral ARC Acquisition I Corp. (NASDAQ: BCARU) today announced the closing of its initial public offering of 25 million units at $10.00 per unit, raising $250 million in gross proceeds. Each unit comprises one Class A ordinary share and one-half of one redeemable public warrant, exercisable at $11.50 per share. Once separated, the shares and warrants are expected to trade on Nasdaq under the symbols “BCAR” and “BCARW,” respectively. The company has granted underwriters a 45-day option to purchase up to an additional 3.75 million units, which could increase total proceeds to $287.5 million. Net proceeds from the offering…

Continue Reading

WednesdayAug 13, 2025 11:35 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20

  Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, will present at the Emerging Growth Conference on Aug. 20, 2025, at 2:20 p.m. ET. The virtual session will feature a corporate update followed by a Q&A, with a live webcast available through the Events section of Clene’s website and via the conference registration link and replays accessible through the conference portal and YouTube channel. To view the full press release, visit https://nnw.fm/xM8p6 About Clene Inc. Clene Inc., (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc.,…

Continue Reading

WednesdayAug 13, 2025 10:53 am

NetworkNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Acquires Go Fast Sports Brand in Move Into Functional Beverage Market 

Golden Triangle Ventures (OTC: GTVH) (“GTV”) reached an agreement with Labor Smart, Inc. (OTC: LTNC) to acquire the Go Fast Sports brand, including all assets, trademarks, inventory and related rights, marking its first major acquisition under incoming CEO Javier Leal. The deal was completed without issuing GTVH stock or convertible notes, as Leal contributed 720 million of his personal LTNC shares to the transaction, calling it a gift to shareholders. Founded in 1996, Go Fast Sports is a lifestyle-driven energy brand with a global following in extreme sports, motorsports and athletic communities, and will anchor GTVH’s Beverages & Health division alongside…

Continue Reading

WednesdayAug 13, 2025 9:22 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Announces Juve Stabia Coppa Italia Opener Against Serie A’s US Lecce

Brera Holdings (NASDAQ: BREA), an Ireland-based multi-club football ownership company, announced that its majority-owned Serie B club S.S. Juve Stabia will face Serie A squad US Lecce in an away match on Aug. 15, 2025, in the Coppa Italia round of 32 at the 32,000-seat Via Del Mare Stadium. Known as “The Other Team of Naples,” Juve Stabia earned the fixture after a strong 2024-25 season, finishing fifth in Serie B and reaching the Serie A promotion playoffs semifinals. The club also recorded the highest market value increase in Serie B last season, up 245% to $32 million from $9.3…

Continue Reading

WednesdayAug 13, 2025 9:00 am

NetworkNewsBreaks – FAVO Capital (OTC: FAVO) Acquires $190 Million Mixed-Use Property 1818 Park in All-Stock Deal

FAVO Capital (OTC: FAVO), a diversified finance company providing alternative revenue-based funding to SMBs, completed its $190 million all-stock and assumption-of-liabilities acquisition of 1818 Park, a Class-A mixed-use property in downtown Hollywood, Florida. The newly built, high-occupancy asset features residential, office, and retail space with long-term leases, delivering stable cash flow and expanding FAVO’s portfolio into income-generating real estate. Former owners led by GCF Development will become long-term equity partners, ensuring operational continuity. Management said the acquisition strengthens FAVO’s balance sheet, broadens its collateral base, supports larger financing lines, and enhances private credit growth while aligning with the company’s long-term, diversified…

Continue Reading